{"organizations": [], "uuid": "047c90dd56b2e6281b74ee64cd3b92c4f6383cf1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pain-therapeutics-resubmits-new-dr/brief-pain-therapeutics-resubmits-new-drug-application-for-remoxy-er-idUSFWN1Q30ZE", "country": "US", "domain_rank": 408, "title": "Pain Therapeutics Resubmits New Drug Application For Remoxy ER", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.717, "site_type": "news", "published": "2018-02-13T21:23:00.000+02:00", "replies_count": 0, "uuid": "047c90dd56b2e6281b74ee64cd3b92c4f6383cf1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pain-therapeutics-resubmits-new-dr/brief-pain-therapeutics-resubmits-new-drug-application-for-remoxy-er-idUSFWN1Q30ZE", "ord_in_thread": 0, "title": "Pain Therapeutics Resubmits New Drug Application For Remoxy ER", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "oxy", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Pain Therapeutics Inc:\n* PAIN THERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR REMOXYÂ® ER, AN ABUSE-DETERRENT, EXTENDED-RELEASE DRUG CANDIDATE FOR THE TREATMENT OF CHRONIC PAIN\n* PAIN THERAPEUTICS INC - COMPANY EXPECTS A SIX-MONTH REVIEW CYCLE BY FDA FOR REMOXY NDA\n* PAIN THERAPEUTICS INC - EXPECTS TO BE NOTIFIED BY FDA OF A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE WITHIN 60 DAYS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T21:23:00.000+02:00", "crawled": "2018-02-14T12:43:54.000+02:00", "highlightTitle": ""}